Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
Sara A. Byron*, William P. D. Hendricks*, Abhinav B. Nagulapally*, Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E. Eslin, Deanna Mitchell, Albert Cornelius, William Roberts, Michael S.[...]
Genomic Analysis and Precision Therapy for Recurrent and Resistant Sarcoma
Javier Oesterheld, Abhinav B Nagulapally, Karl Dykema, William Ferguson, Michael Isakoff, Erin Trovillion, Genevieve Bergendahl, Giselle Saulnier Sholler, Genomic Analysis and Precision Therapy for Recurrent and Resistant Sarcoma, ASPHO Annual Meeting,[...]
9-ING-41, a glycogen synthase kinase 3B inhibitor targets TP53 in pediatric brain tumors ATRT and ETMR
Jason L. Haw, Elizabeth M. Moore, Kimberly McKinney, Karl Dykema, Abhinav Nagulapally, Nury Steuerwald, Giselle S. Sholler. 9-ING-41, a glycogen synthase kinase 3B inhibitor targets TP53 in pediatric brain tumors ATRT[...]
A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma, or alveolar rhabdomyosarcoma
Giselle L. Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael Isakoff, Kevin Bielamowicz, Jacquline Kraveka, Peter Carmeliet, Andy De[...]
Identification of targeted therapies for treatment of Ewing sarcoma
Smith, K, Gandra, D, McKinney, K, Dykema, K, Nagulapally, A, Sholler, GS, Oesterheld, J, Trovillion, E. Identification of targeted therapies for treatment of Ewing sarcoma [abstract]. In: Proceedings of the 113th Annual[...]
Genomic Comparative Analysis of High Risk Neuroblastoma at Diagnosis and Relapse
Abhinav B Nagulapally, Karl Dykema, Javier Oesterheld, William Ferguson, Michael Isakoff, Erin Trovillion, Genevieve Bergendahl, Giselle Saulnier Sholler, Genomic Comparative Analysis of High Risk Neuroblastoma at Diagnosis and Relapse, ASPHO Annual[...]
Integrated proteomic analysis identifies four distinct subtypes of high-risk neuroblastoma
Kristin L. Leskoske, Sara A. Byron, Seema Plaisier, Apurva M. Hegde, Krystine Garcia-Mansfield, Ritin Sharma, Genevieve Bergendahl, Abhinav B. Nagulapally, William Ferguson, Jaqueline Kraveka, Javier Oesterheld, William P.D. Hendricks, Giselle[...]
A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma or alveolar rhabdomyosarcoma
Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline Kraveka, Peter Carmeliet, Andy De[...]
Feasibility and applicability of molecular guided therapy in high grade glioma/diffuse midline glioma: Results from Beat Childhood Cancer NMTRC-009 Molecular Guided Therapy study
Virginia L. Harrod, MD, PhD, Abhinav B. Nagulapally, MS, Elizabeth C. Lewis, Giselle Saulnier Sholler, MD Feasibility and applicability of molecular guided therapy in high grade glioma/diffuse midline glioma: Results from[...]
Targeting Lin28 in ETMR with ODC1 inhibitor DFMO
Austin Goodyke, Shannon Kelly, Joseph Zagorski, Elizabeth VanSickle, Tyler Maser, Caryl Sortwell, Christopher Kemp, Abhinav Nagulapally, Karl Dykema, Giselle Saulnier-Sholler Targeting Lin28 in ETMR with ODC1 inhibitor DFMO, ISPNO 2020, Japan (Virtual)